A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...
In multivariable analysis, six clinicopathologic variables were significantly associated with time to recurrence: ulceration, tumor thickness, tumor location, neurotropism (tumor growth along nerves), ...
Hosted on MSN
Teddi Mellencamp's melanoma: Everything the reality star has said about her cancer diagnosis
After first being diagnosed with stage 2 melanoma in 2022, her cancer progressed to stage 4 in 2025 Real Housewives star Teddi Mellencamp was diagnosed with stage 2 melanoma in 2022 Since then, she ...
A key takeaway from the analysis was that baseline ctDNA levels alone were not significantly predictive or prognostic. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results